About
BlossomHill Therapeutics, Inc.
BlossomHill Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecule medicines that address medical needs in cancer treatment.
Its pipeline includes BH-30643, an OMNI-EGFR inhibitor in clinical development for advanced EGFR-mutant non-small cell lung cancer (NSCLC), BH-501284, and BH-30236, a macrocyclic CLK (Cdc2-like kinase) inhibitor being evaluated in patients with relapsed or refractory acute myeloid leukemia (R/R AML) and higher-risk myelodysplastic syndrome (HR-MDS).
BlossomHill Therapeutics, Inc. was incorporated in 2020 and is based in San Diego, California.
BlossomHill Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:BLSM
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Risk Metrics
Volatility versus the market
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | $18.25 | $19.84 | $18.25 | $19.80 | $19.80 | +1.55 | 102,400 |
| 2026-08-26 | $18.58 | $18.63 | $17.96 | $18.46 | $18.46 | -0.12 | 55,700 |
| 2026-08-25 | $16.10 | $18.80 | $16.10 | $18.42 | $18.42 | +2.32 | 193,500 |
| 2026-08-24 | $16.38 | $16.50 | $15.94 | $16.03 | $16.03 | -0.35 | 156,000 |
| 2026-08-21 | $16.00 | $16.50 | $15.75 | $16.38 | $16.38 | +0.38 | 111,400 |
| 2026-08-20 | $16.21 | $16.27 | $15.60 | $15.80 | $15.80 | -0.41 | 212,000 |
| 2026-08-19 | $16.21 | $16.77 | $16.01 | $16.17 | $16.17 | -0.04 | 192,800 |
| 2026-08-18 | $16.58 | $16.73 | $15.96 | $16.10 | $16.10 | -0.48 | 308,100 |
| 2026-08-17 | $16.14 | $16.42 | $16.00 | $16.38 | $16.38 | +0.24 | 190,700 |
| 2026-08-14 | $16.31 | $16.76 | $16.00 | $16.18 | $16.18 | -0.13 | 324,000 |
| 2026-08-13 | $16.32 | $16.89 | $16.22 | $16.35 | $16.35 | +0.03 | 425,800 |
| 2026-08-12 | $16.52 | $16.88 | $16.17 | $16.24 | $16.24 | -0.28 | 424,200 |
| 2026-08-11 | $16.39 | $16.98 | $16.15 | $16.52 | $16.52 | +0.13 | 328,500 |
| 2026-08-10 | $16.50 | $17.25 | $15.97 | $15.99 | $15.99 | -0.51 | 418,300 |
| 2026-08-07 | $15.75 | $16.05 | $15.25 | $16.00 | $16.00 | +0.25 | 1,757,600 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| SCHEDULE 13D | Aug 18, 2026 | Filing |
| SCHEDULE 13G | Aug 17, 2026 | Filing |
| SCHEDULE 13G | Aug 14, 2026 | Filing |
| SCHEDULE 13D | Aug 13, 2026 | Filing |
| S-8 | Aug 10, 2026 | Securities to be offered to employees in employee benefit plans |
| 8-K | Aug 10, 2026 | Current Report |
| 424B4 | Aug 7, 2026 | Prospectus |
| EFFECT | Aug 6, 2026 | Notice of Effectiveness |
| S-1MEF | Aug 6, 2026 | Registration adding securities to prior Form S-1 registration |
| CERT | Aug 6, 2026 | Certification by an exchange approving securities for listing |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
J. Jean Cui, Ph.D.
President, Chief Executive Officer, Director
Y. Peter Li, Ph.D., MBA
Executive Chairman
Jason Keyes, MBA
Chief Financial Officer, Executive Vice President
Vincent Liptak, J.D., Ph.D., MBA
General Counsel, Executive Vice President
Geoff Oxnard, M.D.
Chief Medical Officer, Executive Vice President
Sundeep Agrawal, M.D.
Director
Bihua Chen, MBA
Director
Carl L. Gordon, Ph.D., CFA
Director
Sheila Gujrathi, M.D.
Director
John Schmid, MBA
Director
